CAYSTON

LOE Approaching

aztreonam

NDAINHALATIONFOR SOLUTION
Approved
Feb 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

12.1 Mechanism of Action Aztreonam is an antibacterial drug [see ] . 12.3 Pharmacokinetics Sputum Concentrations Sputum aztreonam concentrations exhibited considerable variability between patients receiving CAYSTON (75 mg) in clinical trials. The mean sputum concentration 10 minutes following the…

Clinical Trials (5)

NCT06462235Phase 2Recruiting

A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)

Started Sep 2024
48 enrolled
Gram-negative Bacterial Infection
NCT05639647Phase 2Recruiting

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

Started Apr 2023
48 enrolled
Gram-negative Bacterial Infections
NCT04973826Phase 1Completed

Study to Assess the Pharmacokinetics, Safety and Tolerability of Aztreonam-Avibactam in Healthy Chinese Participants.

Started Aug 2021
12 enrolled
Healthy
NCT04486625Phase 1Completed

Pharmacokinetic Study of Aztreonam-Avibactam in Severe Renal Impairment

Started Aug 2020
11 enrolled
Renal Insufficiency
NCT03696290Phase 4Terminated

Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis

Started Oct 2019
34 enrolled
Bronchiectasis Adult